Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis.

Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, Hassan MA, Darling JM, Feld JJ, Akushevich L, Vainorius M, Nelson DR, Fried MW, Brown RS Jr, Terrault NA.

Hepatol Commun. 2019 Aug 7;3(10):1388-1399. doi: 10.1002/hep4.1412. eCollection 2019 Oct.

2.

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.

Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1811-1819.e4. doi: 10.1016/j.cgh.2017.12.037. Epub 2018 Jan 3.

3.

Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS Jr, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR.

Hepatology. 2017 Oct;66(4):1090-1101. doi: 10.1002/hep.29258. Epub 2017 Sep 4.

4.

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR; HCV-TARGET Study Group.

Gastroenterology. 2016 Dec;151(6):1131-1140.e5. doi: 10.1053/j.gastro.2016.08.004. Epub 2016 Aug 24.

5.

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A, Hogervorst FB, Verhoef S, Carpenter J, Clarke C, Scott RJ, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Burwinkel B, Yang R, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nielsen SF, Flyger H, Benitez J, Zamora MP, Perez JI, Menéndez P, Anton-Culver H, Neuhausen S, Ziogas A, Clarke CA, Brenner H, Arndt V, Stegmaier C, Brauch H, Brüning T, Ko YD, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Antonenkova NN, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Spurdle AB, Investigators K; Australian Ovarian Cancer Study Group, Wauters E, Smeets D, Beuselinck B, Floris G, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Olson JE, Vachon C, Pankratz VS, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GG, Zheng W, Hunter DJ, Lindstrom S, Hankinson SE, Kraft P, Andrulis I, Knight JA, Glendon G, Mulligan AM, Jukkola-Vuorinen A, Grip M, Kauppila S, Devilee P, Tollenaar RA, Seynaeve C, Hollestelle A, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Eccles DM, Rafiq S, Tapper WJ, Gerty SM, Hooning MJ, Martens JW, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Brand JS, Humphreys K, Cox A, Reed MW, Luccarini C, Baynes C, Dunning AM, Hamann U, Torres D, Ulmer HU, Rüdiger T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Swerdlow A, Ashworth A, Orr N, Jones M, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Simard J, Dumont M, Soucy P, Eeles R, Muir K, Wiklund F, Gronberg H, Schleutker J, Nordestgaard BG, Weischer M, Travis RC, Neal D, Donovan JL, Hamdy FC, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Schaid DJ, Kelley JL, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Butterbach K, Park J, Kaneva R, Batra J, Teixeira MR, Kote-Jarai Z, Olama AA, Benlloch S, Renner SP, Hartmann A, Hein A, Ruebner M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambretchs S, Doherty JA, Rossing MA, Nickels S, Eilber U, Wang-Gohrke S, Odunsi K, Sucheston-Campbell LE, Friel G, Lurie G, Killeen JL, Wilkens LR, Goodman MT, Runnebaum I, Hillemanns PA, Pelttari LM, Butzow R, Modugno F, Edwards RP, Ness RB, Moysich KB, du Bois A, Heitz F, Harter P, Kommoss S, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Høgdall E, Peissel B, Bonanni B, Bernard L, Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Larson MC, Fogarty ZC, Kalli KR, Liang D, Lu KH, Hildebrandt MA, Wu X, Levine DA, Dao F, Bisogna M, Berchuck A, Iversen ES, Marks JR, Akushevich L, Cramer DW, Schildkraut J, Terry KL, Poole EM, Stampfer M, Tworoger SS, Bandera EV, Orlow I, Olson SH, Bjorge L, Salvesen HB, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Górski B, Gronwald J, Menkiszak J, Høgdall CK, Lundvall L, Nedergaard L, Engelholm SA, Dicks E, Tyrer J, Campbell I, McNeish I, Paul J, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Cai H, Shu XO, Teten RT, Sutphen R, McLaughlin JR, Narod SA, Phelan CM, Monteiro AN, Fenstermacher D, Lin HY, Permuth JB, Sellers TA, Chen YA, Tsai YY, Chen Z, Gentry-Maharaj A, Gayther SA, Ramus SJ, Menon U, Wu AH, Pearce CL, Van Den Berg D, Pike MC, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Song H, Winship I, Chenevix-Trench G, Giles GG, Tavtigian SV, Easton DF, Milne RL.

J Med Genet. 2016 Dec;53(12):800-811. doi: 10.1136/jmedgenet-2016-103839. Epub 2016 Sep 5.

6.

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.

Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S, Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group.

Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13.

7.

Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.

Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, Manns MP, Sherman K, Frazier LM, Sterling R, Mailliard M, Schmidt M, Akushevich L, Vainorius M, Fried MW.

Clin Infect Dis. 2016 Sep 15;63(6):776-783. doi: 10.1093/cid/ciw387. Epub 2016 Jun 19.

8.

The Association Between Body Mass Index and Presenting Symptoms in African American Women with Ovarian Cancer.

Erondu CO, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters E, Schwartz AG, Terry PD, Wallace K, Akushevich L, Wang F, Crankshaw S, Berchuck A, Schildkraut JM, Moorman PG.

J Womens Health (Larchmt). 2016 Jun;25(6):571-8. doi: 10.1089/jwh.2015.5359. Epub 2016 Feb 17.

9.

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.

Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM.

Aliment Pharmacol Ther. 2015 Apr;41(7):671-85. doi: 10.1111/apt.13095. Epub 2015 Jan 28.

10.

A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES).

Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters E, Schwartz AG, Terry P, Wallace K, Akushevich L, Wang F, Crankshaw S, Moorman PG.

BMC Cancer. 2014 Sep 22;14:688. doi: 10.1186/1471-2407-14-688.

11.

Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors.

Schildkraut JM, Iversen ES, Akushevich L, Whitaker R, Bentley RC, Berchuck A, Marks JR.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1709-21. doi: 10.1158/1055-9965.EPI-13-0192. Epub 2013 Aug 5.

12.

Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.

Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM, Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group, Rossing MA, Schildkraut J, Risch H, Goodman MT; Ovarian Cancer Association Consortium.

Cancer Prev Res (Phila). 2013 Aug;6(8):811-21. doi: 10.1158/1940-6207.CAPR-13-0037. Epub 2013 Jun 12.

13.

Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.

Sfakianos GP, Iversen ES, Whitaker R, Akushevich L, Schildkraut JM, Murphy SK, Marks JR, Berchuck A.

Gynecol Oncol. 2013 Apr;129(1):159-64. doi: 10.1016/j.ygyno.2012.12.030. Epub 2012 Dec 26.

14.

Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women.

Grant DJ, Hoyo C, Akushevich L, Iversen ES, Whitaker R, Marks J, Berchuck A, Schildkraut JM.

Gynecol Oncol. 2013 Apr;129(1):173-8. doi: 10.1016/j.ygyno.2012.12.027. Epub 2012 Dec 21.

15.

Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.

Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A.

Int J Gynecol Cancer. 2012 Jan;22(1):9-14. doi: 10.1097/IGC.0b013e318231f140.

16.

Cancer Risk and Behavioral Factors, Comorbidities, and Functional Status in the US Elderly Population.

Akushevich I, Kravchenko J, Akushevich L, Ukraintseva S, Arbeev K, Yashin A.

ISRN Oncol. 2011;2011:415790. doi: 10.5402/2011/415790. Epub 2011 Jul 12.

17.

What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

Il'yasova D, Siamakpour-Reihani S, Akushevich I, Akushevich L, Spector N, Schildkraut J.

Breast Cancer Res Treat. 2011 Nov;130(2):691-7. doi: 10.1007/s10549-011-1719-4. Epub 2011 Aug 18.

18.

Medical cost trajectories and onsets of cancer and noncancer diseases in US elderly population.

Akushevich I, Kravchenko J, Akushevich L, Ukraintseva S, Arbeev K, Yashin AI.

Comput Math Methods Med. 2011;2011:857892. doi: 10.1155/2011/857892. Epub 2011 Jun 1.

19.

Recreational physical activity and ovarian cancer risk and survival.

Moorman PG, Jones LW, Akushevich L, Schildkraut JM.

Ann Epidemiol. 2011 Mar;21(3):178-87. doi: 10.1016/j.annepidem.2010.10.014.

20.

Age trajectories of physiological indices in relation to healthy life course.

Arbeev KG, Ukraintseva SV, Akushevich I, Kulminski AM, Arbeeva LS, Akushevich L, Culminskaya IV, Yashin AI.

Mech Ageing Dev. 2011 Mar;132(3):93-102. doi: 10.1016/j.mad.2011.01.001. Epub 2011 Jan 22.

21.

Dynamic determinants of longevity and exceptional health.

Yashin AI, Arbeev KG, Akushevich I, Arbeeva L, Kravchenko J, Il'yasova D, Kulminski A, Akushevich L, Culminskaya I, Wu D, Ukraintseva SV.

Curr Gerontol Geriatr Res. 2010. pii: 381637. doi: 10.1155/2010/381637. Epub 2010 Sep 30.

22.

Trade-offs between cancer and other diseases: do they exist and influence longevity?

Ukraintseva SV, Arbeev KG, Akushevich I, Kulminski A, Arbeeva L, Culminskaya I, Akushevich L, Yashin AI.

Rejuvenation Res. 2010 Aug;13(4):387-96. doi: 10.1089/rej.2009.0941.

23.

Primary peritoneal and ovarian cancers: an epidemiological comparative analysis.

Grant DJ, Moorman PG, Akushevich L, Palmieri RT, Bentley RC, Schildkraut JM.

Cancer Causes Control. 2010 Jul;21(7):991-8. doi: 10.1007/s10552-010-9525-6. Epub 2010 Mar 23.

24.

Trends in survival and recovery from stroke: evidence from the National Long-Term Care Survey/Medicare data.

Yashin A, Akushevich I, Ukraintseva S, Akushevich L, Arbeev K, Kulminski A.

Stroke. 2010 Mar;41(3):563-5. doi: 10.1161/STROKEAHA.109.572339. Epub 2010 Jan 21.

25.

Ovarian cancer risk factors in African-American and white women.

Moorman PG, Palmieri RT, Akushevich L, Berchuck A, Schildkraut JM.

Am J Epidemiol. 2009 Sep 1;170(5):598-606. doi: 10.1093/aje/kwp176. Epub 2009 Jul 15.

26.

Genetic model for longitudinal studies of aging, health, and longevity and its potential application to incomplete data.

Arbeev KG, Akushevich I, Kulminski AM, Arbeeva LS, Akushevich L, Ukraintseva SV, Culminskaya IV, Yashin AI.

J Theor Biol. 2009 May 7;258(1):103-11. doi: 10.1016/j.jtbi.2009.01.023. Epub 2009 Feb 4.

27.

Studying health histories of cancer: a new model connecting cancer incidence and survival.

Yashin AI, Akushevich I, Arbeev K, Akushevich L, Kulminski A, Ukraintseva S.

Math Biosci. 2009 Apr;218(2):88-97. doi: 10.1016/j.mbs.2008.12.007. Epub 2009 Jan 4.

28.

Cumulative deficits and physiological indices as predictors of mortality and long life.

Kulminski AM, Ukraintseva SV, Culminskaya IV, Arbeev KG, Land KC, Akushevich L, Yashin AI.

J Gerontol A Biol Sci Med Sci. 2008 Oct;63(10):1053-9.

29.

Trade-off between cancer and aging: what role do other diseases play? Evidence from experimental and human population studies.

Yashin AI, Ukraintseva SV, Akushevich IV, Arbeev KG, Kulminski A, Akushevich L.

Mech Ageing Dev. 2009 Jan-Feb;130(1-2):98-104. doi: 10.1016/j.mad.2008.03.006. Epub 2008 Mar 25.

30.

What age trajectories of cumulative deficits and medical costs tell us about individual aging and mortality risk: Findings from the NLTCS-Medicare data.

Yashin AI, Arbeev KG, Kulminski A, Akushevich I, Akushevich L, Ukraintseva SV.

Mech Ageing Dev. 2008 Apr;129(4):191-200. doi: 10.1016/j.mad.2007.12.005. Epub 2008 Feb 1.

31.

Model of hidden heterogeneity in longitudinal data.

Yashin AI, Arbeev KG, Akushevich I, Kulminski A, Akushevich L, Ukraintseva SV.

Theor Popul Biol. 2008 Feb;73(1):1-10. Epub 2007 Sep 18.

32.

Insights on aging and exceptional longevity from longitudinal data: novel findings from the Framingham Heart Study.

Yashin AI, Akushevich IV, Arbeev KG, Akushevich L, Ukraintseva SV, Kulminski A.

Age (Dordr). 2006 Dec;28(4):363-374.

33.

Cumulative index of elderly disorders and its dynamic contribution to mortality and longevity.

Yashin AI, Arbeev KG, Kulminski A, Akushevich I, Akushevich L, Ukraintseva SV.

Rejuvenation Res. 2007 Mar;10(1):75-86.

PMID:
17378754
34.

Stochastic model for analysis of longitudinal data on aging and mortality.

Yashin AI, Arbeev KG, Akushevich I, Kulminski A, Akushevich L, Ukraintseva SV.

Math Biosci. 2007 Aug;208(2):538-51. Epub 2006 Dec 5.

35.

Health decline, aging and mortality: how are they related?

Yashin AI, Arbeev KG, Kulminski A, Akushevich I, Akushevich L, Ukraintseva SV.

Biogerontology. 2007 Jun;8(3):291-302. Epub 2007 Jan 23.

Supplemental Content

Loading ...
Support Center